Is Merck & Company Inc (MRK) overvalued? · P/E 33, rev $16.61B
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Rob Davis.
This page asks whether Merck & Company Inc (MRK) looks expensive on cached numbers — not a short thesis.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
MRK currently screens at market cap $285.12B and trailing P/E 32.5. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MRK 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MRK stock page for the full model, not this heading.
Not investment advice.